Related Experiment Video
Updated: May 10, 2026
11:28
Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
Published on: March 13, 2015
Gaps in pre-rituximab hepatitis B screening: an institutional experience
Kamal K S Abbi1, Matthew Gorris, Roland T Skeel
11University of Toledo Medical Center, Toledo, OH; and 2University of Toledo College of Medicine and Life Sciences, Toledo, OH.
American Journal of Therapeutics
|July 3, 2013
Summary
This study reviewed low-grade lymphoma pretreatment workups, finding significant deviations from National Comprehensive Cancer Network guidelines, particularly in hepatitis B screening. Measures were implemented to improve compliance and patient care.
Area of Science:
- Oncology
- Hematology
Background:
- National Comprehensive Cancer Network (NCCN) guidelines provide a framework for optimal cancer care.
- Pretreatment workup is crucial for accurate staging and treatment planning in low-grade lymphoma.
- Compliance with guidelines ensures standardized and effective patient management.
Purpose of the Study:
- To evaluate the adherence to NCCN guidelines for pretreatment workup in low-grade lymphoma patients.
- To identify specific areas of non-compliance within the pretreatment evaluation process.
- To assess the impact of guideline adherence on patient care.
Main Methods:
- Retrospective chart review of new low-grade lymphoma patients (2005-2011).
- Analysis of key pretreatment workup components: bone marrow biopsy, lactate dehydrogenase (LDH), hepatitis B screening, performance status, and diagnostic radiology.
- Comparison of performed workups against NCCN guideline recommendations.
Main Results:
- 36 out of 53 (68%) patients had pretreatment workup at the center.
- Bone marrow biopsy: 54%; Diagnostic radiology: 97%; LDH levels: 72%.
- Hepatitis B screening was significantly underutilized (19% overall, 25% for rituximab patients), deviating from NCCN guidelines.
Conclusions:
- A notable gap exists in hepatitis B screening compliance for low-grade lymphoma patients, especially those receiving rituximab.
- Implementation of targeted measures improved hepatitis B screening rates.
- Adherence to NCCN guidelines is essential for optimizing pretreatment workup and enhancing patient care in low-grade lymphoma.
